Define Solitary Thyroid Nodule. Describe its investigations and management.

The Concept — the Central Question Is Cancer

A solitary thyroid nodule is a discrete swelling within one lobe of an otherwise normal-feeling thyroid. It is a common presentation, and the entire work-up is built around answering one question: is it malignant? The reassuring background fact is that only about 5–10% of clinically solitary nodules are cancerous — the great majority are benign — but because a missed thyroid cancer is very treatable when caught, every solitary nodule is assessed systematically rather than dismissed.

What a 'solitary' Nodule Actually Is

It is worth knowing that many apparently solitary nodules are not truly solitary: the commonest finding is a dominant or prominent nodule within an occult multinodular goitre, or a benign colloid nodule. Genuinely discrete lesions include a benign follicular adenoma, a thyroid cyst, an area of thyroiditis, and — the one to exclude — a thyroid carcinoma.

Clinical Red Flags for Malignancy

The history and examination look specifically for features that raise the probability of cancer:

• Age extremes (under 20 or over 60) and male sex.
• Rapid growth, or a hard, irregular, fixed nodule.
• Hoarseness (suggesting recurrent laryngeal nerve infiltration) or dysphagia/stridor.
• Cervical lymphadenopathy.
• A history of neck irradiation in childhood, or a family history of thyroid cancer or men syndrome.

Investigations

The nodule is worked up with a logical sequence of tests:

• Thyroid function tests (TSH, T3, T4) — assess function; a functioning ('toxic') nodule that suppresses the TSH is rarely malignant.
• Ultrasound of the neck — characterises the nodule (solid vs cystic) and looks for suspicious features (microcalcification, hypoechogenicity, irregular margins, increased internal vascularity, taller-than-wide shape) and abnormal nodes.
• Fine-needle aspiration cytology (FNAC) — the single most important investigation, giving a cytological category (Thy/Bethesda) that guides management.
• Radioisotope scan — reserved for a nodule with a suppressed TSH: a 'hot' (functioning) nodule is almost always benign, whereas a 'cold' (non-functioning) nodule carries a ~15–20% malignancy risk.

Management — Guided BY Cytology

Treatment follows the FNAC result. A benign (Thy2) nodule is reassured and observed, with surgery only for size, symptoms or cosmesis. A malignant or suspicious (Thy4/Thy5) nodule is treated by thyroidectomy. The crucial category is the follicular lesion (Thy3): because FNAC cannot distinguish a benign follicular adenoma from a follicular carcinoma, these patients undergo a diagnostic hemithyroidectomy (lobectomy) so the whole lesion can be examined histologically. A simple cyst is aspirated, with excision if it recurs or the fluid is bloodstained.

The Cytology Categories

FNAC results are reported in standardised categories (the Thy or Bethesda system) that directly drive management: Thy1 non-diagnostic (repeat the aspirate), Thy2 benign (reassure/observe), Thy3 follicular/indeterminate (diagnostic hemithyroidectomy), Thy4 suspicious of malignancy, and Thy5 diagnostic of malignancy (proceed to appropriate thyroidectomy). This categorisation is why cytology sits at the centre of the pathway — it converts a lump into a management plan.

The Approach in Summary

Put together, the assessment of any solitary nodule is a disciplined sequence: clinical evaluation for red flags → thyroid function tests → ultrasound → FNAC (with an isotope scan only if the TSH is suppressed). The great value of this scheme is that it confidently reassures the ~90% with benign disease while reliably selecting the ~10% who need surgery — and it never relies on clinical impression alone, because a hard fixed nodule can occasionally be benign and a deceptively soft one malignant.

Clinical Examination of the Nodule

Examination of the neck contributes real information that guides the work-up. The nodule is assessed for size, consistency (soft, firm or hard), surface, mobility, and whether it moves on swallowing (confirming a thyroid origin). The examiner palpates for cervical lymphadenopathy (raising the suspicion of malignancy, especially papillary carcinoma), checks for tracheal deviation and retrosternal extension, listens for a bruit, and assesses the patient's clinical thyroid status. A hard, fixed nodule with palpable nodes and hoarseness is clinically worrying, whereas a soft, mobile, solitary nodule that moves freely is more reassuring — though, as always, imaging and cytology, not clinical feel alone, make the diagnosis.

• Malignancy risk of a clinically solitary nodule ≈ 5–10%; of a 'cold' nodule on scan ≈ 15–20%.
• Follicular lesion on FNAC (Thy3) → diagnostic hemithyroidectomy.
• Hot/toxic nodule → almost always benign.

Most solitary nodules are dominant nodules of a multinodular gland.

• Solitary thyroid nodule: the central task is to exclude malignancy (~5–10% are malignant).
• Red flags: age <20 or >60, male, rapid growth, hard/fixed, hoarseness, nodes, neck irradiation, family history/men.
• Investigate with TFTs, ultrasound, FNAC (most important); isotope scan if TSH suppressed (hot = benign, cold = ~15–20% malignant).
• FNAC cannot distinguish follicular adenoma from carcinoma → follicular lesion needs diagnostic hemithyroidectomy.
• Benign → observe; malignant/suspicious → thyroidectomy; cyst → aspirate (excise if recurs/bloody).